Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR/Cas9-mediated validation of candidate Master Regulators Proteins in DMG/GBM Cell Lines

ABSTRACT: Three GBM and three DMG cell lines were selected to be used in a function validation CRISPR screening to elucidate essentiality of canidate Master Regulator proteins

ORGANISM(S): Homo sapiens

PROVIDER: GSE267415 | GEO | 2025/12/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

DMG H3-K27M MAPK-altered methylation data

Project description:Diffuse midline gliomas (DMG) are aggressive tumors with a poor prognosis. In this study, a technique called t-SNE analysis was used to cluster tumors based on their methylation profiles. DMG subtype with a co-occurrence of H3.3K27M and BRAF or FGFR1 mutations have been identified. This subtype has a more favorable prognosis, with a median overall survival of 3 years.

2024-07-30 | E-MTAB-13471 | biostudies-arrayexpress

Generation of Syngeneic Orthotopic DMG Murine Models

Project description:Diffuse Midline Glioma (DMG) syngeneic orthotopic murine mouse models were used as high fidelity model of human DMG tumors as they recapitulate the heterogeneity, cell states and OncoTarget/OncoTreat drug predictions of human DMG tumors.

2025-12-22 | GSE262774 | GEO

Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation

Project description:Characterisation of a new subgroup of DMG lacking H3-K27M mutation that is defined by H3K27me3 loss and EZHIP overexpression that can be detected by IHC. These tumors are distinct from EZHIP-positive posterior fossa ependymomas and are associated with a dismal prognosis. We propose that these EZHIP/H3-WT tumors need to be considered similar to canonical DIPG/DMG, thus extending the spectrum of DMG with PRC2 inhibition beyond H3-K27M mutation

2020-03-20 | E-MTAB-8888 | biostudies-arrayexpress

PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

Project description:H3K27-altered Diffuse Midline Glioma (DMG) is a universally fatal paediatric brainstem tumour. The prevalent driver mutation H3K27M creates a unique epigenetic landscape that may also establish therapeutic vulnerabilities to epigenetic inhibitors. From a wider screen of an epigenetic inhibitor library, we identified PRMT5 inhibitors as amongst the top hits reducing DMG cell viability. Here, we treated HSJD-DIPG-007 +/- the PRMT5 inhibitor LLY-283. RNA-sequencing was performed at 0, 1, 2, 3, 5, 7 and 10 days to assess the changes in gene expression following PRMT5 inhibition in DMG cells. This shows that PRMT5 inhibition changes expression in genes associated with multiple disease relevant phenotypes, including sterol metabolism, differentiation, and the extracellular matrix. By characterising the changes in the transcriptome following PRMT5 inhibition this provides crucial insights into the potential of PRMT5 inhibitors as a treatment for H3K27-altered DMG.

2024-01-05 | GSE230065 | GEO

Szabonella alba strain:DMG-N-6

Project description:Tabrizicola alba DMG-N-6 Genome sequencing and assembly

| PRJNA693311 | ENA

Generation of Drug Perturbational Profiles in SF8628 and DIPG6 DMG Cell Lines

Project description:372 clinically relevant drugs, including FDA-approved and late-stage experimental oncology drugs were tested in both SF8628 and DIPG6 DMG Cell Lines

2025-12-22 | GSE264130 | GEO

Single cell multi-omics profiling of H3-K27M DMG

Project description:Single cell multi-omics profiling of H3-K27M DMG

| PRJNA764213 | ENA

Effect of TIM-3 knockout in the tumoroginesis in the NP53 DMG cell line

Project description:To investigate the function of TIM-3 expression in the regulation of NP53 proliferation and tumorigenesis differentiation, we established DMG cell lines in which each target gene has been knocked out by CRISPR/Cas9.

2023-12-07 | GSE223859 | GEO

Experimental validation of candidate regulators of KRAS transcriptional components.

Project description:We sequenced mRNA from HCC44 and YAPC cell lines stably expressing Cas9, and infecting with indicated gRNAs against regulators of KRAS transcriptional components.

2017-07-10 | GSE84706 | GEO

PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

Project description:PRMT5 inhibition by LLY-283 in HSJD-DIPG-007 DMG cells

| PRJNA957302 | ENA